Supernus Pharmaceuticals (SUPN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

SUPN · Stock Price

USD 52.28+20.58 (+64.92%)

Market Cap: $3.0B

Historical price data

Market Cap: $3.0BPipeline: 75 drugs (25 Phase 3)Patents: 20Founded: 2005HQ: Rockville, United States

Overview

Supernus Pharmaceuticals is a publicly traded CNS-focused biopharmaceutical company with a mission to improve patient lives through innovative neurology and psychiatry treatments. The company has successfully built a commercial foundation with eight marketed products and is advancing a pipeline featuring late-stage candidates for treatment-resistant depression and severe epilepsy. Its strategy combines internal R&D powered by proprietary drug delivery platforms with strategic acquisitions, such as Sage Therapeutics, to solidify its position as a comprehensive CNS therapeutics leader.

NeurologyPsychiatry

Technology Platform

Proprietary drug delivery technology platform designed to optimize pharmacokinetics, improve tolerability, and enable convenient dosing for CNS therapies.

Pipeline

75

75 drugs in pipeline25 in Phase 3

Drug	Indication	Stage
ZULRESSO®	Postpartum Depression	Approved
APOKYN	Parkinson's Disease	Approved
SPN-812	Attention-Deficit/Hyperactivity Disorder (ADHD)	Approved
SPN-812	Attention-Deficit/Hyperactivity Disorder	Approved
100mg SPN-812 + Placebo	Attention-Deficit/Hyperactivity Disorder	Approved

Funding History

1

Total raised:$60M

IPO$60MUndisclosedFeb 8, 2012

FDA Approved Drugs

6

ONAPGONDAFeb 3, 2025

QELBREENDAApr 2, 2021

GOCOVRINDAAug 24, 2017

Opportunities

The acquisition of Sage Therapeutics opens the large, high-need mood disorders market, with SPN-820 representing a major near-term catalyst in treatment-resistant depression.

Continued growth of Qelbree in the expansive ADHD market and successful development of SPN-817 for severe epilepsy offer additional avenues for significant value creation.

Risk Factors

Key risks include commercial execution challenges for recent launches in competitive markets, clinical failure of late-stage pipeline assets SPN-820 and SPN-817, and integration complexities following the transformative Sage Therapeutics acquisition.

Competitive Landscape

Supernus competes with large pharma and specialized biotechs in neurology and psychiatry. Its differentiation stems from proprietary drug delivery technology, a diversified commercial portfolio, and commercial agility. Key competitors include Jazz Pharmaceuticals, UCB, Neurocrine Biosciences, Takeda, and major depression-focused companies.